Osteitis fibrosa cystica is the classic skeletal manifestation of severe, prolonged hyperparathyroidism. It is now less common in settings where primary hyperparathyroidism is detected early, but remains clinically relevant in undiagnosed disease, in areas with limited access to healthcare and, above all, in secondary and tertiary hyperparathyroidism associated with chronic kidney disease. Biologically, it represents a state of high bone turnover sustained by excess PTH, with marked cortical resorption, bone marrow fibrosis and the formation of hemorrhagic cavities and cystic lesions that may resemble so-called brown tumors.
From a clinical perspective, osteitis fibrosa cystica is important because it may initially present with bone pain, fragility fractures, skeletal deformities or focal lesions that mimic neoplastic disease, requiring rigorous diagnostic assessment. Severity depends not only on the extent of radiological abnormalities, but also on the overall endocrine and metabolic context, particularly the balance of calcium, phosphate and vitamin D, renal function and the duration of exposure to the parathyroid stimulus.
Osteitis fibrosa cystica has become relatively uncommon in primary hyperparathyroidism in countries with widespread access to laboratory testing and imaging, because many diagnoses are made during an asymptomatic or mildly symptomatic phase, before the development of the historically characteristic skeletal complications. In this setting, the clinical epidemiology has shifted toward subtler forms of hyperparathyroidism, whereas osteitis fibrosa cystica remains an indicator of advanced disease or delayed diagnosis. When it occurs in primary hyperparathyroidism, it is more likely to be associated with marked hypercalcemia, very high PTH and a substantial increase in alkaline phosphatase, reflecting intense and sustained bone remodeling activity.
At the same time, osteitis fibrosa cystica remains clinically relevant in secondary and tertiary hyperparathyroidism associated with CKD-MBD, in which chronic parathyroid stimulation develops against a background of phosphate retention, reduced calcitriol production, altered FGF23 signaling and skeletal and parathyroid resistance to feedback mechanisms. In these patients, its epidemiological distribution reflects the duration of kidney disease, the adequacy of serum phosphate control and the availability of targeted treatments, including vitamin D analogues, phosphate binders and calcimimetics.
The main risk factors include prolonged uncontrolled hyperparathyroidism, which allows progressive cortical erosion and fibrous replacement of bone marrow. Coexisting vitamin D deficiency amplifies PTH secretion and destabilizes mineral homeostasis, increasing the likelihood of a high-turnover state. Conditions that reduce skeletal reserve, such as advanced age, frailty, low body weight and inflammatory or nutritional comorbidities, may also increase the clinical impact of PTH-induced abnormalities, transforming accelerated remodeling into fractures and disability.
An important epidemiological feature is that osteitis fibrosa cystica may be the first recognized manifestation of an underlying endocrine and metabolic disorder. Focal osteolytic lesions, persistent pain, deformities or fractures disproportionate to the severity of trauma may initially lead to orthopedic or oncological investigations. In these cases, the clinical risk is not limited to the severity of bone disease, but also includes diagnostic error, because a brown tumor may be mistaken for a primary bone neoplasm or metastasis unless the skeletal finding is interpreted together with PTH and serum calcium.
In patients with chronic kidney disease, epidemiology is closely linked to the care pathway, including regular biochemical monitoring, adherence to treatment, dietary phosphate control and dialysis adequacy. Without effective control, hyperparathyroidism may become refractory, with nodular parathyroid growth and progression toward an autonomous phenotype that promotes persistent high bone turnover and severe skeletal complications.
Osteitis fibrosa cystica is the skeletal consequence of chronic PTH excess, irrespective of the cause of hyperparathyroidism. The classic etiological setting is primary hyperparathyroidism, in which inappropriate PTH production, most often caused by a parathyroid adenoma and less commonly by multiglandular hyperplasia or carcinoma, produces accelerated bone remodeling and shifts the balance toward resorption. A second major setting is secondary hyperparathyroidism associated with CKD-MBD, in which PTH rises as an adaptive response to phosphate retention, reduced calcitriol production and relative or fluctuating hypocalcemia, with progressive disruption of feedback mechanisms. At an advanced stage, progression to tertiary hyperparathyroidism leads to more autonomous secretion and a greater risk of skeletal and mineral complications.
From a pathogenetic perspective, PTH acts primarily through its receptors on cells of the osteoblast and stromal lineages, modulating the expression of mediators that regulate osteoclast differentiation and activation. Under physiological conditions, intermittent signaling may produce anabolic effects, but in chronic excess a phenotype of excessive resorption predominates, with increased turnover and structural loss, particularly in cortical bone. Increased remodeling activity does not guarantee greater mechanical strength, because excessively rapid turnover reduces the time available for matrix maturation and mineralization and promotes the accumulation of microdamage.
The pathophysiology of osteitis fibrosa cystica is characterized by a coherent group of macrostructural and microstructural abnormalities. Subperiosteal resorption and endosteal resorption erode the cortex, causing thinning, irregularity and reduced strength, while the marrow may develop fibrosis and proliferation of stromal tissue rich in giant cells. Areas of resorption may evolve into cavities containing hemorrhage and hemosiderin deposits, producing macroscopically brown focal lesions that are often radiolucent on imaging and are clinically described as brown tumors. These lesions are not neoplasms, but manifestations of an extreme and disorganized remodeling microenvironment.
Mineral balance contributes to clinical variability. In primary hyperparathyroidism, increased PTH tends to enhance renal tubular calcium reabsorption, stimulate calcitriol production and increase intestinal absorption, promoting hypercalcemia and relative hypophosphatemia. This setting accelerates bone turnover and produces an additional systemic burden that may manifest with nephrolithiasis, dehydration and neurocognitive abnormalities, making bone disease part of a multisystem disorder. In CKD-MBD, by contrast, hyperphosphatemia and reduced vitamin D activation create a different balance in which PTH remains elevated, but serum calcium may be normal or variable, and skeletal vulnerability results from the interaction among turnover, mineralization quality and uremic comorbidities.
A key factor is the mechanical significance of cortical loss. Cortical bone is essential for resistance to bending and torsion, so diffuse subperiosteal resorption and focal cavitation increase the likelihood of fractures, deformities and pain. This explains why osteitis fibrosa cystica may have a functional impact disproportionate to bone mineral density alone and why assessment must integrate biology, imaging and the clinical picture, avoiding reductive interpretations based on a single parameter.
The clinical manifestations of osteitis fibrosa cystica result from structural alteration of bone and from the metabolic environment that sustains it. Onset may be insidious, with intermittent bone pain, stiffness and progressive reduction in physical performance, or more abrupt when the first manifestation is a fracture caused by skeletal fragility or a focal lesion producing localized pain and functional limitation. Symptom distribution depends on the pattern of skeletal involvement and on the presence of brown tumor-like focal lesions, which may affect the mandible, ribs, pelvis, long bones and spine, producing variable clinical presentations.
During medical history taking, patients may report deep pain worsened by weight bearing, sometimes associated with muscle weakness and easy fatigability. Advanced disease may cause deformities, loss of height due to vertebral collapse and a history of multiple fractures. When osteitis fibrosa cystica results from primary hyperparathyroidism, symptoms of hypercalcemia often coexist, including polyuria, polydipsia, constipation, nausea, reduced appetite, sleep disturbances and neurocognitive abnormalities, directing attention toward an underlying endocrine cause. In patients with CKD, symptoms may overlap with uremic pain, neuropathy or generalized frailty, making correlation with biochemical measurements of PTH, phosphate and vitamin D essential.
The physical examination may reveal bone tenderness on palpation or loading, reduced proximal muscle strength, an antalgic gait and signs of previous fractures. Expansile lesions in craniofacial sites may cause asymmetry, mandibular pain or dental abnormalities, whereas cavitary lesions in long bones may predispose to pathological fractures. In severe disease, functional impairment may be substantial and require multidisciplinary assessment involving orthopedics, nephrology and endocrinology.
A crucial clinical feature is that focal lesions of osteitis fibrosa cystica may mimic oncological disease. Patients may be referred because of a bone mass, a radiolucent osteolytic lesion or persistent pain, raising concern for metastatic disease. In these cases, medical history must include features suggestive of a mineral disorder, such as nephrolithiasis, chronic kidney dysfunction, dialysis treatment, use of medications affecting calcium and phosphate and, when relevant, a family history of parathyroid or other endocrine disorders.
Clinical manifestations are also influenced by the systemic complications of hyperparathyroidism. In primary hyperparathyroidism, nephrolithiasis or nephrocalcinosis may cause lumbar pain, colic and recurrent urinary tract infections, whereas in CKD severe hyperparathyroidism occurs within a broader setting of vascular calcification and increased cardiovascular risk. Osteitis fibrosa cystica is therefore rarely an exclusively skeletal problem, but rather an indicator of complex mineral dysregulation requiring integrated clinical interpretation.
Osteitis fibrosa cystica should be suspected when bone pain, fractures or osteolytic lesions occur together with clinical or biochemical evidence of hyperparathyroidism. In the absence of significant trauma, a disproportionate or recurrent fracture, particularly when associated with increased alkaline phosphatase and abnormalities of serum calcium or serum phosphate, requires targeted investigation. Suspicion increases further when imaging shows characteristic signs of cortical resorption, particularly subperiosteal resorption of the phalanges, skull abnormalities or multiple cavitary lesions.
Advanced chronic kidney disease is a particularly suggestive setting. In patients with CKD, especially those receiving dialysis or with longstanding disease, persistent bone pain, deformities or fractures, together with persistently elevated PTH and hyperphosphatemia, should raise concern for a high-turnover phenotype compatible with osteitis fibrosa. In this context, suspicion has both diagnostic and strategic value, because progression toward refractory hyperparathyroidism may reduce the effectiveness of medical treatment and increase the risk of skeletal and vascular complications.
In primary hyperparathyroidism, suspicion should be high when hypercalcemia is substantial and skeletal or renal manifestations are present. Bone pain, fragility, loss of height, a history of nephrolithiasis and systemic symptoms of hypercalcemia form a coherent clinical pattern that justifies rapid assessment. Even an isolated focal bone lesion, particularly when radiologically described as osteolytic, should prompt measurement of PTH and reconstruction of calcium and phosphate balance, because identification of a parathyroid disorder may completely change the diagnosis and treatment.
Another relevant setting is the differential diagnosis with oncological disease and bone dysplasia. When a report describes multiple lytic lesions, a bone mass or a giant cell tumor, osteitis fibrosa cystica becomes a priority consideration if abnormalities of mineral homeostasis coexist. In such cases, clinical suspicion prevents inappropriate invasive procedures and allows rapid referral for endocrine and metabolic assessment, reducing delays that would worsen skeletal damage.
The condition should also be suspected when functional disability predominates over pain, particularly in frail patients. Marked loss of strength, difficulty walking and progressive loss of independence, when associated with a biochemical profile compatible with hyperparathyroidism and high turnover, may represent the presentation of advanced metabolic bone disease in which osteitis fibrosa cystica is a clinically plausible diagnosis with major therapeutic implications.
The diagnosis of osteitis fibrosa cystica is based on integration of clinical findings, the biochemical profile of mineral homeostasis and skeletal imaging, with one essential requirement: demonstration of hyperparathyroidism and a high bone turnover phenotype compatible with the observed structural abnormalities. The first objective is to define the calcium-phosphate-PTH axis and place the patient within an etiological setting, distinguishing primary from secondary or tertiary hyperparathyroidism, because the therapeutic strategy and skeletal prognosis depend on the cause and reversibility of the disorder.
Biochemical assessment includes total serum calcium and, when required, ionized calcium, interpreted correctly in relation to albumin and hydration status. It also includes serum phosphate, PTH, measured with second-generation or third-generation assays according to availability, 25(OH)D, renal function, magnesium and turnover markers such as total or bone-specific alkaline phosphatase, which is often elevated in states of intense remodeling. Primary hyperparathyroidism commonly produces hypercalcemia with low or low-normal phosphate, whereas in CKD-MBD serum phosphate tends to be elevated and serum calcium is variable. This difference supports interpretation but does not replace comprehensive assessment.
Diagnostic assessment of osteitis fibrosa cystica
First-line imaging is often based on conventional radiography of symptomatic sites and sentinel skeletal regions. Findings such as subperiosteal resorption, cortical erosions, a granular skull appearance, cysts and lytic lesions may be highly suggestive when interpreted in a setting of hyperparathyroidism. Bone densitometry using DXA is useful for quantifying bone mass loss, with particular attention to cortical bone, but it does not independently describe microstructural quality or focal lesions and must therefore be interpreted as part of a broader assessment.
Second-line imaging includes CT and MRI, which are useful for defining the extent and characteristics of focal lesions, assessing fracture risk, identifying compression or involvement of critical structures and planning orthopedic or surgical procedures. In some patients, bone scintigraphy or other functional imaging techniques may help map skeletal involvement, particularly when symptoms are widespread or when differentiation between multiple fractures and active focal lesions is required.
The differential diagnosis is crucial because brown tumors may resemble metastases, multiple myeloma, fibrous dysplasia or giant cell tumors on imaging. In general, consistency between the biochemical profile and skeletal findings strongly supports a metabolic diagnosis and reduces the need for invasive procedures. However, targeted histological evaluation may be indicated when imaging findings are atypical, when there is no clear abnormality of the mineral axis or when the lesion behaves aggressively. Histology must always be interpreted in light of endocrine data to avoid misleading conclusions.
Once osteitis fibrosa cystica has been identified, the diagnostic process must conclude with definition of the cause of hyperparathyroidism and assessment of systemic complications. When primary hyperparathyroidism is suspected, evaluation also includes renal complications such as nephrolithiasis and nephrocalcinosis. In CKD-MBD, attention focuses on calcium and phosphate control, the severity of hyperparathyroidism and the presence of extraskeletal calcifications, because these factors influence therapeutic selection and overall prognosis.
Classification of osteitis fibrosa cystica is useful when it links the skeletal presentation to the endocrine mechanism and clinical risk. The first distinction is etiological and separates disease associated with primary hyperparathyroidism from disease associated with secondary hyperparathyroidism or tertiary hyperparathyroidism in CKD-MBD. This distinction is clinically meaningful because it changes the interpretation of calcium and phosphate, the reversibility of parathyroid stimulation and the likelihood that definitive intervention, such as parathyroidectomy, will be required.
A second classification is morphological and clinical, distinguishing predominantly diffuse disease, characterized by cortical resorption and generalized fragility, from disease with multiple focal lesions, in which brown tumors become the principal clinical feature because of localized pain, deformity or pathological fracture risk. These phenotypes coexist in many patients, but identifying the predominant component is essential for establishing therapeutic priorities, including orthopedic stabilization, pain management and protection of high-risk skeletal segments.
Severity can be assessed across three integrated dimensions. The first is the intensity of the endocrine disorder, with very high PTH and markedly increased turnover markers indicating aggressive remodeling. The second is structural impact, including the number and anatomical location of lesions, fractures, deformities and vertebral involvement. The third is functional impact, measured through pain, limitation of weight bearing, loss of independence and the need for support devices or orthopedic surgery.
In patients with CKD, functional classification of bone metabolism also includes the concept of high turnover as a renal osteodystrophy phenotype, which must be distinguished from low-turnover states because treatment should avoid interventions that worsen bone quality. In this context, osteitis fibrosa cystica represents the archetypal high-turnover disorder and demonstrates that management cannot be based on a single parameter, but requires coherent interpretation of laboratory findings, imaging and clinical history.
Classification must also recognize clinically urgent presentations. Expansile lesions in critical sites, unstable fractures, severe uncontrolled pain and systemic complications of hyperparathyroidism require an accelerated approach in which correction of mineral abnormalities and, when indicated, definitive parathyroid intervention become essential to prevent additional skeletal damage and improve functional outcome.
Treatment of osteitis fibrosa cystica must be built around one central principle: skeletal healing requires correction of the PTH stimulus and stabilization of mineral homeostasis. Orthopedic and symptomatic measures are important, but pathological remodeling continues unless hyperparathyroidism is effectively controlled. The therapeutic strategy is therefore inseparable from etiology and differs between primary hyperparathyroidism and CKD-MBD, although both pathways share common objectives.
In primary hyperparathyroidism associated with osteitis fibrosa cystica, parathyroidectomy is the definitive standard treatment because it removes the source of PTH excess and allows skeletal repair to begin. Preoperative management includes stabilization of calcium balance, optimization of vitamin D status when appropriate and assessment of cardiovascular and renal risk. In patients with severe hypercalcemia or clinical instability, correction of mineral abnormalities becomes a priority in order to reduce acute complications and improve procedural safety.
When surgery cannot be performed immediately or is not feasible, medical treatment aims to reduce the biological burden of PTH excess and hypercalcemia through an individualized approach. Calcimimetics may help control serum calcium and parathyroid secretion in selected patients, while bone-directed interventions may be considered to reduce fracture risk and improve skeletal stability, with careful evaluation of indications and contraindications in each case. Medical treatment does not, however, replace definitive correction when osteitis fibrosa cystica indicates advanced disease, because structural recovery is more reliable when the PTH stimulus is removed.
In patients with CKD-MBD, treatment is based on control of phosphate, calcium and active vitamin D or its analogues, together with calcimimetics when indicated, with the objective of reducing secondary hyperparathyroidism and preventing progression to refractory disease. The choice of treatment combinations depends on CKD stage, dialysis status, serum calcium and phosphate, PTH trends and tolerability. When hyperparathyroidism becomes severe and resistant to medical treatment, parathyroidectomy may also be required in nephrological practice, because persistently very high PTH sustains pathological bone turnover and increases the risk of calcification and systemic complications.
Management after PTH correction, particularly after parathyroidectomy, is a fundamental component of treatment because mineral-depleted bone may rapidly incorporate calcium and phosphate during reconstruction, causing hungry bone syndrome with potentially severe hypocalcemia. The risk is greater when osteitis fibrosa cystica is advanced and alkaline phosphatase is markedly elevated. Prevention and treatment are based on calcium supplementation and, when appropriate, calcitriol, with close monitoring of electrolytes, including magnesium and phosphate, and adjustment of treatment according to clinical and biochemical evolution.
Orthopedic and rehabilitative care is not secondary. Fractures, deformities and lesions in high-risk sites require assessment for stabilization, prevention of further events and functional recovery. Pain control, nutritional optimization and a progressive physical activity program compatible with skeletal stability and cardiovascular status support recovery of muscle mass and independence, which are often impaired by immobility and catabolism associated with the underlying disease.
Effective treatment combines correction of the cause, control of mineral balance and skeletal protection, with close monitoring during critical phases. Osteitis fibrosa cystica is a marker of severe disease and requires a high-intensity clinical strategy, because the useful therapeutic window is the period in which the parathyroid stimulus can be rapidly interrupted and skeletal reconstruction supported safely.
Follow-up of osteitis fibrosa cystica must pursue two parallel objectives: maintaining stable control of hyperparathyroidism and documenting structural and functional skeletal recovery. The initial phase requires more frequent monitoring because correction of the PTH stimulus, particularly after surgery or major therapeutic changes, may cause rapid fluctuations in calcium, phosphate and magnesium. This is especially relevant in patients with very high turnover, in whom bone reconstruction consumes minerals and requires dynamic adjustment of supplementation and related therapies.
Biochemical monitoring includes PTH, serum calcium, serum phosphate, 25(OH)D and turnover markers such as alkaline phosphatase, which help define the trajectory of reduction in pathological remodeling. After parathyroidectomy, the fall in PTH does not immediately coincide with normalization of bone metabolism because restoration requires several months, and alkaline phosphatase may remain elevated or change slowly during reconstruction. In CKD-MBD, follow-up must maintain a clinical balance between correction of hyperparathyroidism and prevention of opposite extremes, such as hypocalcemia or excessive suppression that may promote undesirable skeletal phenotypes.
Imaging is adapted to the initial presentation. Targeted radiographs and, when needed, CT or MRI allow assessment of focal lesion repair, evolution of brown tumors and fracture healing. DXA may be repeated after an appropriate interval to document recovery of bone mass, while recognizing that bone quality and fracture risk reduction also depend on microstructural reconstruction and clinical stabilization, not only on numerical changes in density.
Clinical surveillance must include assessment of pain, motor function, balance and fall risk because functional prognosis depends substantially on muscle recovery and rehabilitation. In patients with fractures or deformities, orthopedic follow-up is integrated with endocrine and metabolic monitoring to coordinate weight-bearing progression, possible procedures and therapeutic correction of mineral homeostasis.
In primary hyperparathyroidism, follow-up also includes monitoring of renal and cardiovascular complications associated with calcium abnormalities. In patients with CKD, follow-up is necessarily multidimensional and integrated with nephrological management, dialysis and prevention of extraskeletal calcification. In both settings, the quality of follow-up is determined by the ability to maintain stable mineral balance and promptly identify recurrent or persistent hyperparathyroidism, because any prolonged period of high turnover reintroduces the risk of cumulative skeletal damage.
The prognosis of osteitis fibrosa cystica depends primarily on how quickly the PTH stimulus is corrected and on the severity of skeletal damage at diagnosis. When hyperparathyroidism is treated effectively, particularly through definitive treatment in primary disease or robust control in CKD-MBD, the skeleton enters a phase of progressive repair, with reduction of pain, functional improvement and remodeling of lesions over time. Recovery is not immediate because cortical reconstruction and microstructural stabilization require several months and may continue for prolonged periods in severe disease.
The main complications are related to skeletal fragility. Pathological fractures, deformities, vertebral collapse and functional limitation are the most consequential outcomes and may result in loss of independence, need for orthopedic surgery and complications of immobility. Brown tumor-like focal lesions may also cause compressive or structural problems depending on their location, occasionally requiring stabilization or selective resection, particularly when severe pain or mechanical risk persists.
A crucial group of complications occurs after treatment, particularly hungry bone syndrome following parathyroidectomy, which may be severe in patients with advanced osteitis fibrosa cystica. Symptomatic hypocalcemia, with paresthesias, cramps, tetany or QT prolongation, requires prompt prevention and treatment with calcium and calcitriol, together with monitoring of magnesium and phosphate. This phase is a predictable complication of healing, and its correct management is an integral part of achieving a favorable prognosis.
In primary hyperparathyroidism, renal complications such as nephrolithiasis and nephrocalcinosis may coexist, affecting overall prognosis and remaining clinically relevant even after correction of the endocrine abnormality, which makes renal surveillance important. In CKD-MBD, prognosis is influenced by kidney disease and cardiovascular risk because calcium and phosphate abnormalities and severe hyperparathyroidism are associated with vascular calcification and cardiovascular events in addition to skeletal complications.
Overall, osteitis fibrosa cystica is a severe but biologically reversible condition when hyperparathyroidism is effectively controlled and skeletal reconstruction is supported by appropriate follow-up. Functional prognosis improves when endocrine and metabolic correction is combined with orthopedic protection, fall prevention and restoration of muscle function, because skeletal damage is most likely to result in disability when it is accompanied by generalized frailty and loss of muscle mass and strength.